The Cancer Biopsy Market Size was valued at USD 30.2 billion in 2023 and is expected to reach USD 56.3 billion by 2031, and grow at a CAGR of 8.1% over the forecast period 2024-2031.
The introduction of cancer biopsy and continuing advances in biopsy techniques are intended to have a significant impact on market growth. In addition, a number of biopsy techniques are used in the field of oncology diagnostics such as endoscopic, bone marrow, skin, needle and surgeon biopsies. The emergence of liquid biopsy in cancer diagnosis, screening, prognosis, and treatment monitoring has sparked significant competition and advancements within the market. Companies actively engaged in adopting or conducting liquid biopsies are considered pivotal catalysts for growth in clinical settings. For example, in June 2023, LabCorp launched a liquid biopsy designed to detect cancer-related biomarkers. This groundbreaking blood test holds the potential to enable cancer patients to initiate highly effective treatments at the earliest feasible stage.
Get more information on Cancer Biopsy Market - Request Sample Report
MARKET DYNAMICS
DRIVERS
Increasing awareness in order to drive growth of the market
The introduction of liquid biopsy is expected to bolster market growth
The introduction of fluid biopsy is expected to be one of the main drivers for growth on the global cancer biopsy market over the forecast period. For example, a liquid biopsy is used to analyse circulating DNACFDNA from cells that are excreted into the bloodstream by all types of tumors in patients with metastatic cancer. Labcorp launched a liquid biopsy for the detection of biomarkers associated with cancer on June 23, 2023. The new Labcorp blood test may help cancer patients get the best possible treatment as quickly as possible. The objective of this test is to analyze the genetic makeup of both advanced and metastatic solid tumors.
RESTRAINTS
The possibilities of reimbursement that are not known
The growth of the market is being hampered by a large amount of diagnostic costs
The high cost of diagnosis is one of the main factors likely to hinder growth in the cancer biopsy market. Diagnostic tests of cancer are very expensive and increase the financial burden on families of patients. Therefore, these tests are not accessible to a middle-class patient population who does not have insurance. Furthermore, the cost of detecting cancer is not covered by several private insurers and this makes it difficult to use screening tools. However, with increasing medical tourism and diagnostic solutions becoming more affordable, this scenario is expected to change in the next few years.
OPPORTUNITIES
Increasing the geriatric population
Rising burden of cancer across the globe
The growth opportunities for the cancer biopsy market are expected to be considerable in view of an increasing incidence of cancer worldwide. For instance, with the increasing prevalence of cancer, the use/adoption of cancer biopsy is also increasing with the rapid pace. As per projections from the American Cancer Society (ACS), the United States is anticipated to witness over 1,958,311 new cancer cases and 609,821 cancer-related deaths in 2023. Additionally, according to the Indian Council of Medical Research (ICMR), India may experience a 12.0% rise in cancer cases over the next five years, with approximately 1.5 million individuals expected to be afflicted by this non-communicable disease by 2025.
CHALLENGES
Market growth is hampered by technological and clinical challenges
The technical and medical challenges are another factor that hinders the growth of the global biopsy market for cancer. Several technical and clinical challenges related to the introduction of image guided biopsy in order to overcome costs and efficiency problems with surgery biopsies exist. For instance, some patients are predisposed to psychosocial, physical, or mental comorbidities that may restrict their participation & involvement in image-guided breast biopsy. The biopsy of the tissue is painful, invasive, costly and time consuming in spite of its informative nature; however, sometimes it's not necessary to remove tumour heterogeneity.
Since Russia’s invasion of Ukraine, damage to key healthcare infrastructures, power outages, and shortages of medicine and food supplies have represented major hurdles for patients requiring time-critical interventions. In particular, oncology services have experienced significant disruption due to the fact that hospitals and health care providers must adjust their attention to trauma emergencies. Furthermore, the conflict has begun to transfer a portion of Ukraine's cancer burden to neighboring nations. New solutions for managing the various aspects of cancer care in Ukraine are needed, given the unique problems associated with this disease. An important online meeting, the ECOASCO Special Meeting on the Impact of the War in Ukraine on Cancer, with over 200 participants, was held by the European Cancer Organization and the American Society of Clinical Oncologists. The ECO-ASCO Special Network on the Impact of War in Ukraine aims to bolster cooperation and coordination among oncology societies, cancer patient associations, and all entities striving to aid Ukrainian cancer patients. It aims to disseminate information in local languages, highlight and bolster ongoing efforts for Ukrainian patients, advocate to the World Health Organization (WHO), European Union (EU), and national governments, and adapt its strategies according to the evolving needs of the population while fostering partnerships with other relevant organizations.
To enhance the health outcomes of the communities they serve, cancer centers must grasp the effects of external elements like unemployment, health insurance coverage, poverty, and accessibility of healthcare services. This understanding is crucial for identifying systemic factors that contribute to inferior cancer-related outcomes among the populations they cater to. However, conducting ecological studies to analyze population-level trends faces challenges due to shifts in health policies over time, variations in the enforcement of regulations, population movements into and out of specific areas, and localized differences at the community level. For instance, disparities in regulations related to tobacco have been linked to stable smoking rates in rural regions, whereas urban areas report a decline in smoking rates.
By Product
Instruments
Kits And Consumables
Services
Kits and consumables, as they are an integral part of the biopsy process across different stages with substantial investments made by key players in this sector, accounted for a revenue share of 61.71% from 2023. There is also a significant increase in the number of patients around the world who require instruments and kits that are efficient, accurate and rapid. Several developments in the area of instruments, kits and consumables have been observed with regard to cancer biopsy. For example, Summit Medical LLC announced in December 2022 the launch of a single use instrument to its Cervical Rotating Biopsy Punch product line that supports rapid diagnostic processes such as cancer diagnosis.
By Type
Tissue Biopsies
Needle Biopsies
Fine Needle Aspiration (FNA)
Core Needle Biopsy (CNB)
Surgical Biopsies
Liquid Biopsies
Others
The most lucrative revenue was generated by tissue biopsy and accounted for 62.3% of all revenues in 2023. It has been widely used for different cancer diagnosis applications, and continues to be seen as an essential component of biopsies. This is due to the strong research activities which have contributed to this segment's dominance of the global market over the forecast period, in assessing its safety and effectiveness. In the coming years, advances to improve tissue biopsy procedures should continue to maintain its dominant position on the worldwide market. On the other hand, Cernostics is working on an assay to diagnose Barrett's Esophagus in cancer patients. This diagnostic uses biopsy images which are digitally scanned to help analyse and quantify changes that occur at the level of cells or molecules in tissue.
Need any customization research on Cancer Biopsy Market - Enquire Now
By Application
Colorectal Cancer
Cervical Cancers
Lung Cancers
Prostate Cancers
Skin Cancers
Blood Cancers
Kidney Cancers
Liver Cancers
Pancreatic Cancers
Ovarian Cancers
Others
In 2023, breast cancer accounted for a market share of 15.5% and the same is expected to increase at an accelerated compound annual growth rate over the forecast period. Breast cancer has the highest prevalence rate. Around 1 in 8 U.S. women develop invasive breast cancer as per the U.S. breast cancer statistics. For example, in 2022, in the US, women will be diagnosed with 287,851 new cases of invasive breast cancer, 51,401 cases of DCIS, and 43,251 will pass away from breast cancer.
Regional Analysis
The North America market, accounting for 40.7% of the total revenue generated in 2023, was the most profitable. The dominant share of North America in the forecast is expected to remain, with the US contributing significantly towards regional revenues. Furthermore, distributors and manufacturers in this region are seeking to distribute new kits that can be used rapidly for diagnostic purposes. In addition, the profitable strategies set out by the relevant government bodies are largely supportive of an increasing adoption of liquid biopsies throughout the United States. The framework, developed in recent years by the US Food and Drug Administration, relies on regulatory strategies for liquid biopsy-based oncology diagnostics.
Europe and Asia Pacific are also expected to experience strong growth in the biopsy market worldwide due to the growing prevalence of cancer, an ageing population, increased awareness among people and further adoption of liquid biopsies in these regions. For example, the European Liquid Biopsy Academy (ELBA) project, which is an Innovative Training Network (ITN), seeks to advance the promising technology of liquid biopsies from its initial stages and integrate it into clinical practice, particularly focusing on early diagnosis of Non-Small Cell Lung Cancer (NSCLC). Furthermore, as the cancer burden continues to grow, there is a corresponding increase in the adoption of cancer biopsies.
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Some of the major players are as follows: ANGLE Plc, BD (Becton, Dickinson and Company), Biocept, Inc., Danaher, F. Hoffmann-La Roche Ltd., Hologic, Inc., Illumina, Inc., Myriad Genetics, Qiagen N.V., Thermo Fisher Scientific, Inc, and other players.
In January 2023, Qiagen announced the acquisition of Verogen, a NGS Forensics Company that will contribute to strengthening its product portfolio and thus increase its global footprint.
In June 2023, QIAGEN reports that as part of the National Initiative in Denmark to provide sequencing solutions for patients with cancer, it is providing variant interpretation and reporting software called QIAGEN Clinical Insight QCI Interpret.
In January 2023, C2i Genomics, a leading company in the field of cancer intelligence, has joined forces with Onco DNA, which specializes in precision medicine for patients with cancer and hereditary disorders, to expand its activities into Europe's market. Their common goal is to advance the field of personalised medicine for patients who are affected by cancer or inherited diseases.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$30.2 Billion |
| Market Size by 2031 | US$ 56.3 Billion |
| CAGR | CAGR of 8.1% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Instruments, Kits and Consumables, Services) • By Type (Tissue Biopsies, Liquid Biopsies, Others) • By Application (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Liver Cancers, Pancreatic Cancers, Ovarian Cancers, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | ANGLE Plc, BD (Becton, Dickinson and Company), Biocept, Inc., Danaher, F. Hoffmann-La Roche Ltd., Hologic, Inc., Illumina, Inc., Myriad Genetics, Qiagen N.V., Thermo Fisher Scientific, Inc, and other players. |
| DRIVERS | • Oncology Disorders are becoming more common, and liquid biopsies are becoming more popular. • Technological Advancement • Inherited Oncology Disorders and Genetic Testing are becoming more well-known. |
| OPPORTUNITIES | • Biopsy Procedure-Related Risks • Reimbursement possibilities that are unclear |
Kits and consumables, which are essential at various phases of biopsies, made for the greatest sales share
North America had the largest share of almost 40.0 percent. Throughout the projected period, the area is expected to maintain its lead, with the United States contributing significantly to regional revenue.
Cancer Biopsy Market is divided into three segments and they are By Product, By Type, and By Application
Biopsy Procedure-Related Risks, Reimbursement possibilities that are unclear are the restraints of the Cancer Biopsy market.
Cancer Biopsy market is expected grow at a CAGR of 7.6% over the forecast period 2024-2031.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Impact Analysis
5.1 Impact of Russia-Ukraine Crisis
5.2 Impact of Economic Slowdown on Major Countries
5.2.1 Introduction
5.2.2 United States
5.2.3 Canada
5.2.4 Germany
5.2.5 France
5.2.6 UK
5.2.7 China
5.2.8 Japan
5.2.9 South Korea
5.2.10 India
6. Value Chain Analysis
7. Porter’s 5 Forces Model
8. Pest Analysis
9. Cancer Biopsy Market, By Product
9.1 Introduction
9.2 Trend Analysis
9.3 Instruments
9.4 Kits and Consumables
9.5 Services
10. Cancer Biopsy Market, By Type
10.1 Introduction
10.2 Trend Analysis
10.3 Tissue Biopsies
10.3.1 Needle Biopsies
10.3.1.1 Fine Needle Aspiration (FNA)
10.3.1.2 Core Needle Biopsy (CNB)
10.3.2 Surgical Biopsies
10.4 Liquid Biopsies
10.5 Others
11. Cancer Biopsy Market, By Application
11.1 Introduction
11.2 Trend Analysis
11.3 Breast Cancer
11.4 Colorectal Cancer
11.5 Cervical Cancers
11.6 Lung Cancers
11.7 Prostate Cancers
11.8 Skin Cancers
11.9 Blood Cancers
11.10 Kidney Cancers
11.11 Liver Cancers
11.12 Pancreatic Cancers
11.13 Ovarian Cancers
11.14 Others
12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 USA
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 Eastern Europe
12.3.1.1 Poland
12.3.1.2 Romania
12.3.1.3 Hungary
12.3.1.4 Turkey
12.3.1.5 Rest of Eastern Europe
12.3.2 Western Europe
12.3.2.1 Germany
12.3.2.2 France
12.3.2.3 UK
12.3.2.4 Italy
12.3.2.5 Spain
12.3.2.6 Netherlands
12.3.2.7 Switzerland
12.3.2.8 Austria
12.3.2.9 Rest of Western Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 India
12.4.3 Japan
12.4.4 South Korea
12.4.5 Vietnam
12.4.6 Singapore
12.4.7 Australia
12.4.8 Rest of Asia Pacific
12.5 The Middle East & Africa
12.5.1 Middle East
12.5.1.1 UAE
12.5.1.2 Egypt
12.5.1.3 Saudi Arabia
12.5.1.4 Qatar
12.5.1.5 Rest of the Middle East
11.5.2 Africa
12.5.2.1 Nigeria
12.5.2.2 South Africa
12.5.2.3 Rest of Africa
12.6 Latin America
12.6.1 Brazil
12.6.2 Argentina
12.6.3 Colombia
12.6.4 Rest of Latin America
13. Company Profiles
13.1 ANGLE Plc
13.1.1 Company Overview
13.1.2 Financial
13.1.3 Products/ Services Offered
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 BD (Becton, Dickinson and Company)
13.2.1 Company Overview
13.2.2 Financial
13.2.3 Products/ Services Offered
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 Biocept, Inc.
13.3.1 Company Overview
13.3.2 Financial
13.3.3 Products/ Services Offered
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 Danaher
13.4.1 Company Overview
13.4.2 Financial
13.4.3 Products/ Services Offered
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 F. Hoffmann-La Roche Ltd.
13.5.1 Company Overview
13.5.2 Financial
13.5.3 Products/ Services Offered
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Hologic, Inc.
13.6.1 Company Overview
13.6.2 Financial
13.6.3 Products/ Services Offered
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 Illumina, Inc.
13.7.1 Company Overview
13.7.2 Financial
13.7.3 Products/ Services Offered
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 Myriad Genetics
13.8.1 Company Overview
13.8.2 Financial
13.8.3 Products/ Services Offered
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 Qiagen N.V.
13.9.1 Company Overview
13.9.2 Financial
13.9.3 Products/ Services Offered
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 Thermo Fisher Scientific, Inc
13.10.1 Company Overview
13.10.2 Financial
13.10.3 Products/ Services Offered
13.10.4 SWOT Analysis
13.10.5 The SNS View
14. Competitive Landscape
14.1 Competitive Benchmarking
14.2 Market Share Analysis
14.3 Recent Developments
14.3.1 Industry News
14.3.2 Company News
14.3.3 Mergers & Acquisitions
15. Use Case and Best Practices
16. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Interventional oncology Market Size was valued at USD 3.145 billion in 2023 and is expected to reach USD 6.862 billion by 2032 and grow at a CAGR of 9.07% over the forecast period 2024-2032.
The Respiratory Syncytial Virus Therapeutics Market size was USD 1.37 Bn in 2023 & will reach USD 4.05 Bn by 2031 & grow at a CAGR of 14.5% by 2024-2031.
The Biological Safety Cabinet Market Size was valued at USD 212.04 million in 2023 and is expected to reach USD 412.42 million by 2032 and grow at a CAGR of 7.73% over the forecast period 2024-2032.
The IoT Medical Devices Market Size was valued at USD 41.4 billion in 2023 and is expected to reach USD 503.6 billion by 2032 and grow at a CAGR of 32.0% over the forecast period 2024-2032.
The Medical Equipment Financing Market size was valued at USD 148 Billion In 2023 & is estimated to reach USD 340.5 Billion by 2032 and increase at a CAGR of 9.7% between 2024 and 2032.
The Healthcare IT Consulting Market Size was valued at USD 50.1 billion in 2023 and is expected to reach USD 168.14 billion by 2032 and grow at a CAGR of 14.4% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
